BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 18714356)

  • 1. OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation.
    Cui Y; Ying Y; van Hasselt A; Ng KM; Yu J; Zhang Q; Jin J; Liu D; Rhim JS; Rha SY; Loyo M; Chan AT; Srivastava G; Tsao GS; Sellar GC; Sung JJ; Sidransky D; Tao Q
    PLoS One; 2008 Aug; 3(8):e2990. PubMed ID: 18714356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation.
    Ying J; Li H; Seng TJ; Langford C; Srivastava G; Tsao SW; Putti T; Murray P; Chan AT; Tao Q
    Oncogene; 2006 Feb; 25(7):1070-80. PubMed ID: 16247458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer.
    Sellar GC; Watt KP; Rabiasz GJ; Stronach EA; Li L; Miller EP; Massie CE; Miller J; Contreras-Moreira B; Scott D; Brown I; Williams AR; Bates PA; Smyth JF; Gabra H
    Nat Genet; 2003 Jul; 34(3):337-43. PubMed ID: 12819783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma.
    Qiu GH; Tan LK; Loh KS; Lim CY; Srivastava G; Tsai ST; Tsao SW; Tao Q
    Oncogene; 2004 Jun; 23(27):4793-806. PubMed ID: 15122337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic identification of ADAMTS18 as a novel 16q23.1 tumor suppressor frequently silenced in esophageal, nasopharyngeal and multiple other carcinomas.
    Jin H; Wang X; Ying J; Wong AH; Li H; Lee KY; Srivastava G; Chan AT; Yeo W; Ma BB; Putti TC; Lung ML; Shen ZY; Xu LY; Langford C; Tao Q
    Oncogene; 2007 Nov; 26(53):7490-8. PubMed ID: 17546048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic silencing of the 3p22 tumor suppressor DLEC1 by promoter CpG methylation in non-Hodgkin and Hodgkin lymphomas.
    Wang Z; Li L; Su X; Gao Z; Srivastava G; Murray PG; Ambinder R; Tao Q
    J Transl Med; 2012 Oct; 10():209. PubMed ID: 23050586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAS-mediated epigenetic inactivation of OPCML in oncogenic transformation of human ovarian surface epithelial cells.
    Mei FC; Young TW; Liu J; Cheng X
    FASEB J; 2006 Mar; 20(3):497-9. PubMed ID: 16384911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation.
    Seng TJ; Low JS; Li H; Cui Y; Goh HK; Wong ML; Srivastava G; Sidransky D; Califano J; Steenbergen RD; Rha SY; Tan J; Hsieh WS; Ambinder RF; Lin X; Chan AT; Tao Q
    Oncogene; 2007 Feb; 26(6):934-44. PubMed ID: 16862168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic deregulations of Wnt/β-catenin and transforming growth factor beta-Smad pathways in esophageal cancer: Outcome of DNA methylation.
    Singh V; Singh AP; Sharma I; Singh LC; Sharma J; Borthakar BB; Rai AK; Kataki AC; Kapur S; Saxena S
    J Cancer Res Ther; 2019; 15(1):192-203. PubMed ID: 30880778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic inactivation of TSLC1 gene in nasopharyngeal carcinoma.
    Hui AB; Lo KW; Kwong J; Lam EC; Chan SY; Chow LS; Chan AS; Teo PM; Huang DP
    Mol Carcinog; 2003 Dec; 38(4):170-8. PubMed ID: 14639656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-specific methylation of the 8p22 tumor suppressor gene DLC1 is an epigenetic biomarker for Hodgkin, nasal NK/T-cell and other types of lymphomas.
    Ying J; Li H; Murray P; Gao Z; Chen YW; Wang Y; Lee KY; Chan AT; Ambinder RF; Srivastava G; Tao Q
    Epigenetics; 2007; 2(1):15-21. PubMed ID: 17965626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of opioid binding protein/cell adhesion molecule-like promoter methylation in bladder carcinoma.
    Duarte-Pereira S; Paiva F; Costa VL; Ramalho-Carvalho J; Savva-Bordalo J; Rodrigues A; Ribeiro FR; Silva VM; Oliveira J; Henrique R; Jerónimo C
    Eur J Cancer; 2011 May; 47(7):1106-14. PubMed ID: 21273058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic disruption of interferon-gamma response through silencing the tumor suppressor interferon regulatory factor 8 in nasopharyngeal, esophageal and multiple other carcinomas.
    Lee KY; Geng H; Ng KM; Yu J; van Hasselt A; Cao Y; Zeng YX; Wong AH; Wang X; Ying J; Srivastava G; Lung ML; Wang LD; Kwok TT; Levi BZ; Chan AT; Sung JJ; Tao Q
    Oncogene; 2008 Sep; 27(39):5267-76. PubMed ID: 18469857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protocadherin20 Acts as a Tumor Suppressor Gene: Epigenetic Inactivation in Nasopharyngeal Carcinoma.
    Chen T; Long B; Ren G; Xiang T; Li L; Wang Z; He Y; Zeng Q; Hong S; Hu G
    J Cell Biochem; 2015 Aug; 116(8):1766-75. PubMed ID: 25736877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TFPI-2 is a putative tumor suppressor gene frequently inactivated by promoter hypermethylation in nasopharyngeal carcinoma.
    Wang S; Xiao X; Zhou X; Huang T; Du C; Yu N; Mo Y; Lin L; Zhang J; Ma N; Murata M; Huang G; Zhang Z
    BMC Cancer; 2010 Nov; 10():617. PubMed ID: 21062455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of OPCML expression and the correlation with CpG island methylation and LOH in ovarian serous carcinoma.
    Chen H; Ye F; Zhang J; Lu W; Cheng Q; Xie X
    Eur J Gynaecol Oncol; 2007; 28(6):464-7. PubMed ID: 18179137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylation of OPCML promoter in ovarian cancer tissues predicts poor patient survival.
    Zhou F; Tao G; Chen X; Xie W; Liu M; Cao X
    Clin Chem Lab Med; 2014 May; 52(5):735-42. PubMed ID: 24327526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and promoter methylation status of OPCML and its functions in the inhibition of cell proliferation, migration, and invasion in breast cancer.
    Lian B; Li H; Liu Y; Chai D; Gao Y; Zhang Y; Zhou J; Li J
    Breast Cancer; 2021 Mar; 28(2):448-458. PubMed ID: 33108608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid-binding protein/cell adhesion molecule-like (OPCML) gene and promoter methylation status in women with ovarian cancer.
    Czekierdowski A; Czekierdowska S; Szymanski M; Wielgos M; Kaminski P; Kotarski J
    Neuro Endocrinol Lett; 2006 Oct; 27(5):609-13. PubMed ID: 17159813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OPCML gene promoter methylation and gene expression in tumor and stroma cells of invasive cervical carcinoma.
    Ye F; Zhang SF; Xie X; Lu WG
    Cancer Invest; 2008 Jul; 26(6):569-74. PubMed ID: 18584347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.